← All verdicts
Verdict

Data Unavailable

Every analyzed stock in Data Unavailable — 2,921 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.
"Data Unavailable" by: Model value (price vs DCF) Owner-earnings return (equity bond)

This lens: price against our probability-weighted DCF value (P/IV). Its own forward record began accruing on 2026-09-10 (daily snapshots); until a year of it exists, the panel below tests the nearest cousin we can measure point-in-time — cheap on book value — and says so.

Market state today: Calm — the S&P 500 closed 3.1% below its 1-year high (as of 2026-09-16). Our rule, the same one used to split every backtest on this site: sell-off = 10% or more below the 1-year high, borderline from 5%, calm otherwise. A further 7.2% fall from here would put us in a sell-off. Since 2006 the market has been in a sell-off 16.6% of the time, across 13 episodes (red bands).
2007200920112013201520172019202120232025
S&P 500 (SPY, adjusted) distance from its trailing 1-year high, weekly. Amber band: borderline (−5% to −10%). Red band: sell-off (below −10%). The dot is today. History to 2026-08-19 from the research database; today from the live feed.
Backtest · point in time · 8,702 entries in the study

Does this screen work? The record for exactly these filters

Screen tested: Proxy: price-to-book ≤ 1.2 (undervalued band has no point-in-time history yet) · bought the day of the annual report, held 12 months
Probable Buy every company that met this screen on the day it filed its annual report, hold 12 months: on average it beat the S&P 500 by +12.6 pts (1,427 entries, 311 companies, very unlikely to be luck). 50% of entries beat the S&P; 25% beat it by 30 points or more; 30% trailed it by 20 points or more. Owning everything instead averaged +1.7 pts, so the screen's edge is +10.9 pts.
+12.6 ptsvs S&P, average
50%beat the S&P
25%up 30+ pts vs S&P
30%down 20+ pts vs S&P
+14.0 ptsvs small caps, 12 mo
−15.1 pts 2019worst year to buy ?
6.1luck check ?
Does the holding period matter?3 mo: +2.3 pts 49% beat6 mo: +4.6 pts 49% beat12 mo: +12.6 pts 50% beat24 mo: +21.8 pts 46% beat3 yr, per yr: +1.3 pts 40% beat
Market state at entryCompany-yearsvs S&P 12 movs small caps
Calm ◀ today1,245+7.9 pts t 4.6+10.1 pts
Sell-off (S&P ≥10% off high)182+44.5 pts t 4.0+40.7 pts
Sector (SEC group)nvs S&P 12 mo3 yrs / yr
Industrials & manufacturing466+13.0 pts t 4.0−2.2 pts
Energy126+7.4 pts t 1.2−7.8 pts
Other115+8.4 pts t 1.8+3.8 pts
Tech hardware & semis113+10.9 pts t 1.6+2.3 pts
Services96+11.9 pts t 2.7+12.2 pts
Retail & consumer87+17.2 pts t 2.1+10.2 pts
Finance & real estate72−1.7 pts t -0.5−2.4 pts
Utilities65+5.6 pts t 0.6−1.2 pts
Construction53+13.2 pts t 1.7−2.4 pts
Biotech & pharma44+47.1 pts t 1.6+10.0 pts
Telecom & media43+14.0 pts t 0.7−6.3 pts
Software & IT services35+39.9 pts t 1.8+1.2 pts

Holds up out of sample? Before 2018: +10.7 pts (n 629, t 6.0). From 2018: +14.0 pts (n 798, t 4.1). Same sign in both halves.

Year2010201120122013201420152016201720182019202020212022202320242025
vs S&P+13 pts+5 pts+14 pts+18 pts−4 pts−4 pts+22 pts+12 pts−3 pts−15 pts+87 pts+8 pts+17 pts−9 pts−7 pts+15 pts
n254310610178841118178991297276108121115

Read the research behind this screen: Price-to-book still sorts, across all sizes → · Test your own combination in the Screen Lab →

Our model values are recomputed daily but were never stored historically, so this band cannot be backtested honestly yet. Daily snapshots began 2026-09-10; a true record accrues from there. Until then the nearest tested cousin is shown — cheap on book value — and labelled as a proxy. Point-in-time: each entry is one company bought at the first close after its 10-K filing date, using only filings available that day, held 12 months; result = total return minus SPY over the same months (vs IWM for 12 months; 3-yr annualised). Survivorship-tilted universe; no costs; read spreads, not levels. Educational, hypothetical, before costs.

Sort by: A–Z Riskiest Most overvalued Most shorted Buyers' strike Largest
NUW
Nuveen AMT-Free Municipal Value Fund
Valuation N/A
Unknown
Price$13.49
Model IV—
P/IV—
Limited data — see page
NVA
Nova Minerals Ltd
Valuation N/A
Basic Materials Risk 51 · Elevated
Price$6.14
Model IV—
P/IV—
Limited data — see page
NVAWW
Nova Minerals Ltd
Valuation N/A
Basic Materials Risk 42 · Elevated
Price$31.40
Model IV—
P/IV—
Limited data — see page
NVAX
NOVAVAX INC
Valuation N/A
Healthcare Risk 37 · Moderate
Price$9.42
Model IV—
P/IV—
Market implies +37.0%/yr vs model +2.0% · above model
NVCR
NovoCure Ltd
Valuation N/A
Healthcare Risk 50 · Elevated
Price$16.22
Model IV—
P/IV—
Market implies +35.6%/yr vs model +5.2% · above model
NVCT
Nuvectis Pharma, Inc.
Valuation N/A
Healthcare Risk 37 · Moderate
Price$23.99
Model IV—
P/IV—
Limited data — see page
NVG
Nuveen AMT-Free Municipal Credit Income Fund
Valuation N/A
Unknown
Price$11.62
Model IV—
P/IV—
Limited data — see page
NVMI
NOVA LTD.
Valuation N/A
Healthcare Risk 43 · Elevated
Price$371.81
Model IV—
P/IV—
Limited data — see page
NVNI
Nvni Group Ltd
Valuation N/A
Technology Risk 61 · High
Price$0.95
Model IV—
P/IV—
Limited data — see page
NVNIW
Nvni Group Ltd
Valuation N/A
Technology Risk 54 · Elevated
Price$0.02
Model IV—
P/IV—
Limited data — see page
NVNO
enVVeno Medical Corp
Valuation N/A
Healthcare Risk 43 · Elevated
Price$10.49
Model IV—
P/IV—
Limited data — see page
NVO
NOVO NORDISK A S
Valuation N/A
Healthcare
Price$43.07
Model IV—
P/IV—
Limited data — see page
NVTS
Navitas Semiconductor Corp
Valuation N/A
Technology Risk 33 · Moderate
Price$11.63
Model IV—
P/IV—
Market implies +9.7%/yr vs model +50.0% · below model
NVX
NOVONIX Ltd
Valuation N/A
Technology Risk 40 · Elevated
Price$2.98
Model IV—
P/IV—
Limited data — see page
NWAX
New America Acquisition I Corp.
Valuation N/A
Financial Services
Price$10.13
Model IV—
P/IV—
Limited data — see page
NWG
NatWest Group plc
Valuation N/A
Financial Services
Price$18.62
Model IV—
P/IV—
Limited data — see page
NWGL
CL Workshop Group Ltd
Valuation N/A
Industrials Risk 42 · Elevated
Price$1.21
Model IV—
P/IV—
Limited data — see page
NXDT
NEXPOINT DIVERSIFIED REAL ESTATE TRUST
Valuation N/A
Financial Services Risk 36 · Moderate
Price$5.32
Model IV—
P/IV—
Limited data — see page
NXE
NexGen Energy Ltd.
Valuation N/A
Basic Materials Risk 52 · Elevated
Price$9.85
Model IV—
P/IV—
Limited data — see page
NXG
NXG NextGen Infrastructure Income Fund
Valuation N/A
Unknown
Price$56.19
Model IV—
P/IV—
Limited data — see page
NXGL
NEXGEL, INC.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.28
Model IV—
P/IV—
Market implies -50.0%/yr vs model +50.0% · below model
NXL
Nexalin Technology, Inc.
Valuation N/A
Healthcare Risk 31 · Moderate
Price$4.82
Model IV—
P/IV—
Market implies +111.9%/yr vs model +20.3% · above model
NXP
NUVEEN SELECT TAX FREE INCOME PORTFOLIO
Valuation N/A
Unknown
Price$13.66
Model IV—
P/IV—
Limited data — see page
NXTC
NextCure, Inc.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$7.00
Model IV—
P/IV—
Limited data — see page
NXTS
Nexentis Technologies Inc.
Valuation N/A
Healthcare Risk 33 · Moderate
Price$1.62
Model IV—
P/IV—
Market implies +31.2%/yr vs model +15.0% · above model
NYAX
Nayax Ltd.
Valuation N/A
Technology Risk 42 · Elevated
Price$45.12
Model IV—
P/IV—
Limited data — see page
NYXH
Nyxoah SA
Valuation N/A
Healthcare Risk 51 · Elevated
Price$1.60
Model IV—
P/IV—
Limited data — see page
NZF
Nuveen Municipal Credit Income Fund
Valuation N/A
Unknown
Price$11.28
Model IV—
P/IV—
Limited data — see page
OABI
OmniAb, Inc.
Valuation N/A
Industrials Risk 38 · Moderate
Price$4.07
Model IV—
P/IV—
Market implies +52.7%/yr vs model +2.0% · above model
OACC
Oaktree Acquisition Corp. III Life Sciences
Valuation N/A
Financial Services
Price$10.77
Model IV—
P/IV—
Limited data — see page
OACCU
Oaktree Acquisition Corp. III Life Sciences
Valuation N/A
Financial Services
Price$11.00
Model IV—
P/IV—
Limited data — see page
OACCW
Oaktree Acquisition Corp. III Life Sciences
Valuation N/A
Financial Services
Price$0.89
Model IV—
P/IV—
Limited data — see page
OBA
Oxley Bridge Acquisition Ltd
Valuation N/A
Financial Services
Price$10.32
Model IV—
P/IV—
Limited data — see page
OBAI
Our Bond, Inc.
Valuation N/A
Communication Services Risk 64 · High
Price$0.32
Model IV—
P/IV—
Limited data — see page
OBAWU
Oxley Bridge Acquisition Ltd
Valuation N/A
Financial Services
Price$10.38
Model IV—
P/IV—
Limited data — see page
OBAWW
Oxley Bridge Acquisition Ltd
Valuation N/A
Financial Services
Price$0.25
Model IV—
P/IV—
Limited data — see page
OBE
OBSIDIAN ENERGY LTD.
Valuation N/A
Energy Risk 32 · Moderate
Price$12.97
Model IV—
P/IV—
Limited data — see page
OBIO
Orchestra BioMed Holdings, Inc.
Valuation N/A
Healthcare Risk 40 · Elevated
Price$6.12
Model IV—
P/IV—
Market implies +44.1%/yr vs model +15.0% · above model
OBTC
Osprey Bitcoin Trust
Valuation N/A
Financial Services Risk 32 · Moderate
Price$24.38
Model IV—
P/IV—
Limited data — see page
OCCI
OFS Credit Company, Inc.
Valuation N/A
Unknown
Price$2.62
Model IV—
P/IV—
Limited data — see page
OCCIM
OFS Credit Company, Inc.
Valuation N/A
Unknown
Price$25.19
Model IV—
P/IV—
Limited data — see page
OCCIN
OFS Credit Company, Inc.
Valuation N/A
Unknown
Price$24.96
Model IV—
P/IV—
Limited data — see page
OCGN
Ocugen, Inc.
Valuation N/A
Healthcare Risk 60 · High
Price$1.02
Model IV—
P/IV—
Market implies +70.9%/yr vs model +15.0% · above model
OCS
Oculis Holding AG
Valuation N/A
Healthcare
Price$10.56
Model IV—
P/IV—
Limited data — see page
OCSAW
Oculis Holding AG
Valuation N/A
Healthcare
Price$3.83
Model IV—
P/IV—
Limited data — see page
OCTV
Octave Intelligence plc
Valuation N/A
Technology Risk 48 · Elevated
Price$18.54
Model IV—
P/IV—
Limited data — see page
OCUL
OCULAR THERAPEUTIX, INC
Valuation N/A
Healthcare Risk 31 · Moderate
Price$10.49
Model IV—
P/IV—
Market implies +55.6%/yr vs model +4.5% · above model
ODC
Oil-Dri Corp of America
Valuation N/A
Consumer Cyclical Risk 33 · Moderate
Price$86.26
Model IV—
P/IV—
Limited data — see page
ODD
Oddity Tech Ltd
Valuation N/A
Consumer Defensive Risk 57 · Elevated
Price$17.95
Model IV—
P/IV—
Limited data — see page
ODTX
Odyssey Therapeutics, Inc.
Valuation N/A
Healthcare Risk 58 · Elevated
Price$21.99
Model IV—
P/IV—
Limited data — see page
ODV
Osisko Development Corp.
Valuation N/A
Basic Materials Risk 52 · Elevated
Price$2.31
Model IV—
P/IV—
Limited data — see page
ODVWZ
Osisko Development Corp.
Valuation N/A
Basic Materials Risk 51 · Elevated
Price$0.08
Model IV—
P/IV—
Limited data — see page
ODYS
Odysight.ai Inc.
Valuation N/A
Technology Risk 27 · Moderate
Price$3.31
Model IV—
P/IV—
Limited data — see page
OFAL
OFA Group
Valuation N/A
Industrials Risk 76 · High
Price$0.59
Model IV—
P/IV—
Market implies +54.3%/yr vs model +2.0% · above model
OFRM
Once Upon a Farm, PBC
Valuation N/A
Consumer Defensive Risk 51 · Elevated
Price$16.98
Model IV—
P/IV—
Limited data — see page
OGC
OceanaGold Corp
Valuation N/A
Basic Materials
Price$30.19
Model IV—
P/IV—
Limited data — see page
OGEN
ORAGENICS INC
Valuation N/A
Healthcare Risk 33 · Moderate
Price$0.49
Model IV—
P/IV—
Market implies +48.4%/yr vs model +15.0% · above model
OGI
ORGANIGRAM GLOBAL INC.
Valuation N/A
Healthcare Risk 32 · Moderate
Price$1.05
Model IV—
P/IV—
Limited data — see page
OIA
Invesco Municipal Income Opportunities Trust
Valuation N/A
Unknown
Price$5.85
Model IV—
P/IV—
Limited data — see page
OIM
OneIM Acquisition Corp.
Valuation N/A
Financial Services
Price$10.12
Model IV—
P/IV—
Limited data — see page